Lymphoproliferative diseases encompass a broad spectrum of disorders characterized by the uncontrolled proliferation of lymphocytes. Conditions under this umbrella include lymphoma, myeloma, lymphoid hyperplasia, and Waldenström's macroglobulinemia. Translational medicine, often referred to as "Bedside-to-Bench-to-Bedside" research, is a rapidly advancing field that bridges clinical practice and basic science. Breakthroughs in translational research have provided new understandings of molecular subtypes, mechanisms, and biomarkers specific to various lymphoproliferative diseases. These insights pave the way for improved diagnostic accuracy, better prediction of therapy responses, and the development of personalized treatment strategies.

This Research Topic will spotlight "Bedside-to-Bench-to-Bedside" research using sample-based methodologies, clinical cohorts, and foundational studies to deepen our understanding of lymphoproliferative diseases. Our goals include elucidating the mechanisms of disease initiation and progression, refining diagnostic and stratification techniques, improving clinical decision-making through novel molecular insights, and promoting personalized therapy applications. Additionally, we aim to explore preventive and control strategies to ultimately enhance patient outcomes by pinpointing new therapeutic targets.
An exciting and emerging area of focus within this field is the role of natural killer (NK) cells and innate lymphoid cells (ILCs) in the context of lymphoproliferative diseases and their immunotherapy. NK cells and ILCs are critical components of the innate immune system, known for their roles in early defense against malignancies and their potential in immunotherapeutic approaches.

For this Research Topic, we welcome submissions of original articles, case series, and review articles involving both sample/patient-derived data and foundational research. Contributions might explore, but are not limited to, the following areas:

o Spatial Dynamics and Cellular Interactions: Investigating the spatial structure and cell-to-cell interactions within lymphoproliferative diseases, including how
NK cells and ILCs interact with malignant cells.
o Molecular Mechanisms: Understanding the molecular underpinnings of lymphoproliferative diseases, particularly how alterations in NK cell and ILC function contribute to disease progression and therapeutic responses.
o Biomarker Discovery: Identifying biomarkers for diagnosing or stratifying patients, with a focus on markers that reveal insights into NK cell and ILC activity.
o Therapeutic Innovations: Discovering and validating novel therapeutic targets, including treatments that harness or modify NK cells and ILCs for improved efficacy against lymphoproliferative disorders.
o Response and Outcomes: Evaluating treatment responses and clinical outcomes, particularly how therapies modulating NK cells and ILCs influence individual patient outcomes

Submit your idea

Articles

Frontiers in Immunology

Submit your idea

Impact